Global Gene Fusion Testing Market to Surge to USD 2.5 Billion by 2035, Driven by Rising Cancer Cases

The global gene fusion testing market, valued at US$ 0.7 billion in 2024, is poised for substantial expansion, projected to reach US$ 2.5 billion by 2035. The industry is set to grow at a strong CAGR of 12.1% from 2025 to 2035, supported by the rising incidence of cancer and the growing emphasis on personalized medicine, which relies heavily on precise genomic profiling. As healthcare systems increasingly adopt molecular diagnostics to guide targeted therapies, demand for advanced gene fusion testing technologies continues to accelerate.

The gene fusion testing market is set to experience substantial expansion over the next few years, largely due to the continuous upgradations in genomic technologies and increased involvement of gene fusion in different cancers. Gene fusion events are pivotal in cancer diagnostics and targeted therapies, which are generally used in cancer types like lung cancer, leukemia, and sarcomas.

Dive Deeper into Data: Get Your In-Depth Sample Now! https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86836

Gene fusion testing is a major source of information used by oncologists to know what gene fusions are. They are the sequences where two genes combine to form a new one. These fusions, which have been identified in lung cancer, breast cancer, and blood cancers mostly, are usually at the forefront of cancer biomarkers.

Market Segmentation

The market can be segmented based on several key factors:

By Service Type

Diagnostic Testing: The largest and fastest-growing segment, focused on detecting gene fusions in patient samples to guide clinical treatment decisions.
Research Testing: Involves the use of gene fusion assays in preclinical and clinical studies to discover new fusion events and validate targeted therapies.
By Sourcing Type (Technology)

The choice of testing platform is crucial, with each offering different advantages:

Next-Generation Sequencing (NGS): Expected to dominate the market. NGS is a high-throughput, comprehensive method capable of detecting both known and novel fusions, especially RNA-based NGS.
Fluorescence In Situ Hybridization (FISH): A traditional, reliable technique for detecting specific fusions, often used as a confirmatory test.
Polymerase Chain Reaction (PCR) / Reverse Transcription-PCR (RT-PCR): Quick and cost-effective for detecting a limited number of known fusion variants.
Immunohistochemistry (IHC): Used as a cost-effective, rapid screening tool to detect the presence of the resulting fusion protein.
By Application (Indication)

Solid Tumors: Includes prevalent cancers such as Non-Small Cell Lung Cancer (NSCLC), sarcomas, thyroid cancer, and rare fusions like $NRG1$ fusions (seen in pancreatic cancer).
Hematological Malignancies: Includes blood cancers like leukemias, where fusions like the classic $BCR-ABL$ in Chronic Myeloid Leukemia (CML) are foundational biomarkers.
By End-User (Industry Vertical)

Hospitals and Diagnostic Laboratories: Constitute the primary end-users, driving demand for routine clinical testing.
Pharmaceutical and Biotechnology Companies: Heavy users of gene fusion testing for companion diagnostic development and clinical trials related to targeted therapy drugs.
Academic and Research Centers: Focus on discovery and translational research into new gene fusions and testing methodologies.
🗺️ Regional Analysis

North America: Expected to hold the largest market share. This is driven by high per capita healthcare spending, advanced healthcare infrastructure, high awareness of personalized medicine, and favorable reimbursement policies for comprehensive genomic profiling (CGP).
Asia-Pacific (APAC): Projected to be the fastest-growing region. Growth is propelled by increasing cancer incidence, rapidly expanding healthcare infrastructure, government initiatives for cancer screening, and increasing adoption of personalized medicine in emerging economies like China and India.
Europe: A mature market with strong growth, supported by established research communities and a focus on integrating targeted therapies into clinical guidelines across countries like the U.K., Germany, and France.
🚀 Market Drivers and Challenges

Market Drivers

Increasing Cancer Incidence: The global rise in cancer cases associated with gene fusion mutations is the fundamental driver.
Shift to Personalized Medicine: Gene fusion testing is essential for selecting targeted therapies (e.g., TRK inhibitors for $NTRK$ fusions) and companion diagnostics, dramatically improving patient outcomes.
Technological Advancements: Continued innovation in NGS and liquid biopsy (non-invasive testing) makes gene fusion detection more accessible, accurate, and rapid.
Supportive Regulatory Environment: Regulatory approvals from agencies like the FDA for tissue-agnostic therapies targeting specific fusions (e.g., $NTRK$ fusions) accelerate test adoption.
Market Challenges

High Cost and Reimbursement Barriers: Advanced NGS panels can be expensive, and reimbursement for certain tests or in particular regions remains complex and inconsistent.
Complexity and Standardization: The testing process is technically complex, and a lack of standardization across different laboratory assays can lead to varying results and interpretation challenges.
Tissue Availability/Quality: Obtaining sufficient, high-quality tumor tissue for comprehensive molecular testing, especially from small biopsies, remains a significant hurdle.
Shortage of Skilled Professionals: A lack of specialized molecular pathologists and trained laboratory personnel in emerging markets limits test deployment.
💡 Market Trends and Future Outlook

The market's future will be defined by the following trends:

Liquid Biopsy Adoption: Non-invasive gene fusion testing using liquid biopsy (analyzing cell-free nucleic acids in blood) is a major trend, offering easier monitoring and assessment in patients where tissue biopsy is difficult.
AI and Machine Learning Integration: Artificial Intelligence (AI) is being leveraged to analyze complex genomic data, predict gene fusion status, and improve the efficiency and accuracy of test interpretation.
Comprehensive Genomic Profiling (CGP): The move towards broad NGS panels that simultaneously test for gene fusions, mutations, and other alterations is becoming the standard of care, conserving precious tissue samples.
Decentralization of Testing: Simplified, rapid, and automated testing platforms, such as some in-vitro diagnostics (IVDs) for PCR/FISH/IHC, are being developed for use in local hospital labs, improving turnaround time.
🔬 Key Market Study Points

NGS Dominance: Track the continued expansion of NGS platforms and the development of cost-effective, high-throughput assays.
Reimbursement Policy: Monitor changes in national and regional reimbursement for CGP and specific gene fusion tests, as policy shifts are major determinants of clinical uptake.
Liquid Biopsy vs. Tissue: Analyze the balance of adoption between tissue-based and liquid biopsy testing, particularly for monitoring minimal residual disease (MRD).
Emerging Biomarkers: Investigate the clinical and commercial impact of newly discovered actionable gene fusions.
Buy this Premium Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=86836<ype=S

🤝 Competitive Landscape and Recent Developments

The Gene Fusion Testing Market is highly competitive, featuring both established multinational diagnostic and pharmaceutical companies and specialized genomics firms. Key players are engaged in strategic initiatives like product launches, collaborations, and mergers/acquisitions to expand their portfolios and geographic reach.

Key Market Players

Major companies driving the market include:

Roche (via acquisitions and diagnostic arms)
Illumina (NGS technology provider)
Guardant Health (Leader in liquid biopsy solutions)
Amoy Diagnostics Co., Ltd.
Arima Genomics, Inc.
Biocartis NV (Focus on rapid molecular diagnostics)
Danaher Corporation
F. Hoffmann-La Roche Ltd.
Recent Developments

Product Launches: Companies like Biocartis have launched new rapid, lab-workflow solutions for gene fusion testing, such as the Idylla GeneFusion Assay (launched in March 2021), designed to detect multiple fusions in a single cartridge.
Collaborations: Arima Genomics announced an agreement with Protean BioDiagnostics (January 2023) to develop an NGS-based gene fusion testing service using Arima's novel genomic technology for identifying actionable fusions in tumor tissues.
Focus on Rare Fusions: Increased R&D and clinical focus on rare, yet targetable, fusions like $NRG1$ fusion, leading to the development of specific diagnostic assays and corresponding therapies.
Explore Latest Research Reports by Transparency Market Research:

Thyroid Cancer Diagnostics Market - https://www.transparencymarketresearch.com/thyroid-cancer-diagnostics-market.html

Ovarian Cancer Diagnostics Market - https://www.transparencymarketresearch.com/ovarian-cancer-diagnostics-market.html

Specimen Collection Cards Market - https://www.transparencymarketresearch.com/specimen-collection-cards-market.html

Lateral Flow Assay Market - https://www.transparencymarketresearch.com/lateral-flow-assay-market.html

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com

This release was published on openPR.